Drugs With ‘Unsupported Price Increases’ Add $5bn To US Spending – ICER
Pharmaceutical Research and Manufacturers of America describes report as “flawed” and designed to advance the “false narrative that spending on medicines in increasing.”
You may also be interested in...
Revenue from migraine prophylaxis Aimovig shrank from Q2 levels, while cholesterol-lowering Repatha volume increased, but sales came in below consensus.
If nothing else, the purported draft may be a preview of what Democrats might do if they prevail in 2020. Proposal calls for HHS price negotiation, international reference pricing, price inflation rebates and structural Medicare Part D changes.
US government moves ahead with enforcement action while several court decisions remain pending on the viability of its interpretation of the law governing the 340B outpatient drug discount program. Underscoring industry’s confidence in its opposing view, Merck & Co. recently joined the companies that are restricting discounts to contract pharmacies.